Dr. Joseph Geraci is interviewed about some of the technologies NetraMark is developing and how they can be used to understand patient subpopulations in a new deeper way

October 1, 2018


Here one can access our Whitepaper which reviews the state of drug development and how NetraMark is providing next generation machine learning methods to disrupt this industry. We review patient stratification, deep phenotyping, drug repositioning, and placebo response and how we are addressing these challenges.